Mizuho recommends buying shares of EyePoint Pharmaceuticals on the recent weakness. The firm has a Buy rating on the shares with a $39 price target. The company made a series of incremental announcements yesterday, including the addition of three “experienced and high quality retinal specialists” to its scientific advisory board, the FDA’s conditional acceptance of a new trade name, Duravyu, for its lead asset, EYP-1901, and that it remains on track for its key upcoming catalysts in 2024, the analyst tells investors in a research note. The firm is “overall pleased by the various pieces of news.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EYPT:
- EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- EyePoint reports inducement grants under Nasdaq listing rule
- Bad News for Eyepoint Pharma Stock: This New Risk Has Been Added
- EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments